Harry D Bear

8PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 22, 2026
Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?

|Sep 02, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Apr 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Feb 28, 2025
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.

Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay

|Mar 07, 2022
A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim.

Joseph Mort, Shipra Maheshwari, Nayanika Basu

|Mar 17, 2021
Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.

Zheng Liu, Chunqing Guo, Swadesh K Das

Pageof 2

Frequent Collaborators

2 joint publications

Sung-Bae Kim

2 joint publications

Eric Hahnen

2 joint publications

Karen Gelmon

2 joint publications

Frederik Marmé